

Journal für  
**Urologie und Urogynäkologie**

Zeitschrift für Urologie und Urogynäkologie in Klinik und Praxis

**Does an Extended Pelvic Lymph Node  
Dissection Improve Outcome in  
Bladder Cancer?**

Liedberg F

*Journal für Urologie und*

*Urogynäkologie 2010; 17 (Sonderheft*

*6) (Ausgabe für Österreich), 12-13*

Homepage:

[www.kup.at/urologie](http://www.kup.at/urologie)

Online-Datenbank mit  
Autoren- und Stichwortsuche

Indexed in Scopus

Member of the



[www.kup.at/urologie](http://www.kup.at/urologie)

Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz

P. b. b. 022031116M, Verlagspostamt: 3002 Purkersdorf, Erscheinungsort: 3003 Gablitz

**Erschaffen Sie sich Ihre  
ertragreiche grüne Oase in  
Ihrem Zuhause oder in Ihrer  
Praxis**

**Mehr als nur eine Dekoration:**

- Sie wollen das Besondere?
- Sie möchten Ihre eigenen Salate,  
Kräuter und auch Ihr Gemüse  
ernten?
- Frisch, reif, ungespritzt und voller  
Geschmack?
- Ohne Vorkenntnisse und ganz  
ohne grünen Daumen?

**Dann sind Sie hier richtig**



# Does an Extended Pelvic Lymph Node Dissection Improve Outcome in Bladder Cancer?

F. Liedberg

Lymph node dissection in bladder cancer were originally introduced by Skinner, when he 1982 reported new impressing survival data in patients with lymph node metastasis submitted to a meticulous lymph node dissection [1]. The question whether extended pelvic lymph node dissection improves survival in bladder cancer treated with radical cystectomy entails a large number of controversial aspects and difficult issues. To interpret the available literature some related questions can be raised:

## ■ Which Template is the Optimal Extended Template?

The lack of internationally accepted definitions of limited, standard and extended lymph node dissections in the literature is the main reason for the difficulties when interpreting the available literature. Some authors consider that an extended dissection ends where at the ureteric crossing of the common iliac vessels [2], the aortic bifurcation is considered as an extended dissection by others [3], whereas the inferior mesenteric artery is a possible upper limit according to some urologists [4]. To gain knowledge about location of lymph node metastasis in bladder cancer several lymph node mapping studies have been performed [3, 5–9]. However, when interpreting these lymph node mapping studies, one must be aware of the possible overlap of lymph node basins and anatomic assignment of extirpated nodes. This might also explain why almost the same materials have been used as arguments „for“ [6] and „against“ [7] a sentinel node region located in the endopelvic area. Still there is some support in the literature that some patients have isolated lymph node metastases above the iliac bifurcation [3, 5, 6]. Thus, an extended lymphadenectomy in bladder cancer is up to the aortic bifurcation, especially as

these patients not necessarily show a worse outcome as compared with lymph node positive patients with positive nodes below the iliac bifurcation [10].

## ■ In the Absence of Randomized Studies, what are the Methodological Flaws in the Studies Available Regarding Extent of Lymphadenectomy and Survival?

Awaiting results from the German randomized multicenter study (AB 25/02-LEA) comparing lymph node dissection to the iliac bifurcation with dissection to the inferior mesenteric artery at cystectomy, presently only retrospective studies are available. Even if the results in these studies seem promising with regard to survival [11–16], the Will-Rogers-phenomenon [17] probably affects all these series to some extent [18].

## ■ Which Patients Should be Submitted to an Extended Lymph Node Dissection at Radical Cystectomy?

A thorough lymph node dissection and proper investigation of the lymph node specimen in an unselected cystectomy series in our hospital identified as many as 43 % of the patients as lymph node positive [3], some of these patients will receive adjuvant chemotherapy. An increasing number of elderly patients, many with significant comorbidity are nowadays submitted to radical cystectomy. As cure can be achieved with surgery only, also in presence of nodal disease [18], it seems reasonable to perform an extended lymph node dissection in these patients also, as they would poorly tolerate adjuvant chemotherapy. In each patient this has to be balanced against possible side effects due to a cephalad lymph node dissection, i.e. dam-

age to autonomic nerves, possible surgical complications and prolonged surgical time. In order to make a correct distinction, knowledge about complications in the own institution is essential [19].

## ■ Are there any Secondary Benefits of Extended Lymph Node Dissection?

It is obvious that an extended lymph node dissection improves staging. Whether cystectomy combined with such dissection, plus or minus adjuvant chemotherapy, might translate into improve survival is unknown at present [20]. Pelvic recurrence after radical cystectomy almost inevitably leads to death. Furthermore, symptoms from pelvic recurrence often is difficult to palliate [21]. Proponents of extended lymph node dissection has shown decreasing incidence of pelvic recurrence after an appropriate lymph node dissection [22, 23].

## ■ Conclusions

Lymph node metastasis is a common finding at radical cystectomy affecting as many as 43 % of operated patients [2]. An extended dissection up to the aortic bifurcation has the best possibility to extirpate all diseased nodes, data from a randomized German study will hopefully soon tell us, if this assumption is evidence based.

## Literature:

1. Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. *J Urol* 1982; 128: 34–6.
2. Karl A, Carroll PR, Gschwend JE, Knuchel R, Montorsi F, Stief CG, et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. *Eur Urol* 2009; 55: 826–35.
3. Liedberg F, Chebil G, Davidsson T, Gudjonsson S, Mansson W. Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. *J Urol* 2006; 175: 84–8.
4. Stein JP. Lymphadenectomy in bladder cancer: how high is „high enough“? *Urol Oncol* 2006; 24: 349–55.
5. Jensen JB, Ulhoi BP, Jensen KM. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy

and lymph node dissection to the level of the inferior mesenteric artery. *BJU Int* 2010; 106: 199–205.

6. Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. *J Urol* 2004; 171: 139–44.

7. Abol-Enein H, El-Baz M, Abd El-Hameed MA, Abdel-Latif M, Ghoneim MA. Lymph node involvement in patients with bladder cancer treated with radical cystectomy: a patho-anatomical study – a single center experience. *J Urol* 2004; 172: 1818–21.

8. Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. *J Urol* 2004; 171: 1830–4.

9. Roth B, Wissmeyer MP, Zehnder P, Birkhauser FD, Thalmann GN, Krause TM, et al. A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. *Eur Urol* 2010; 57: 205–11.

10. Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. *J Urol* 2007; 178: 1218–23.

11. Holmer M, Bendahl PO, Davidsson T, Gudjonsson S, Mansson W, Liedberg F. Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference? *World J Urol* 2009; 27: 521–6.

12. Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE. Outcome after radical cystec-

tomy with limited or extended pelvic lymph node dissection. *J Urol* 2008; 179: 873–8.

13. Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. *J Urol* 1998; 160: 2015–9.

14. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. *BJU Int* 2000; 85: 817–23.

15. Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. *Cancer* 2008; 112: 2401–8.

16. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. *J Clin Oncol* 2004; 22: 2781–9.

17. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. *N Engl J Med* 1985; 312: 1604–8.

18. Suttman H, Kamradt J, Lehmann J, Stockle M. Improving the prognosis of patients after radical cystectomy. Part I: the role of lymph node dissection. *BJU Int* 2007; 100: 1221–4.

19. Liedberg F. Early complications and morbidity of radical cystectomy. *Eur Urol Suppl* 2010; 9: 25–30.

20. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. *Eur Urol* 2005; 48: 189–99.

21. Dhar NB, Jones JS, Reuther AM, Dreicer R, Campbell SC, Sanii K, et al. Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder. *BJU Int* 2008; 101: 969–72.

22. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today – a homogeneous series without neoadjuvant therapy. *J Clin Oncol* 2003; 21: 690–6.

23. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol* 2001; 19: 666–75.

### **Correspondence:**

*Fredrik Liedberg, PhD, F.F.E.B.U.*

*Section of Urology*

*Växjö County Hospital*

*SE-351 85 Växjö, Sweden*

*E-Mail: fredrik.liedberg@ltkronoberg.se*

# Mitteilungen aus der Redaktion

## Besuchen Sie unsere zeitschriftenübergreifende Datenbank

[Bilddatenbank](#)

[Artikeldatenbank](#)

[Fallberichte](#)

## e-Journal-Abo

Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.

Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.

Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

[Bestellung e-Journal-Abo](#)

## Haftungsausschluss

Die in unseren Webseiten publizierten Informationen richten sich **ausschließlich an geprüfte und autorisierte medizinische Berufsgruppen** und entbinden nicht von der ärztlichen Sorgfaltspflicht sowie von einer ausführlichen Patientenaufklärung über therapeutische Optionen und deren Wirkungen bzw. Nebenwirkungen. Die entsprechenden Angaben werden von den Autoren mit der größten Sorgfalt recherchiert und zusammengestellt. Die angegebenen Dosierungen sind im Einzelfall anhand der Fachinformationen zu überprüfen. Weder die Autoren, noch die tragenden Gesellschaften noch der Verlag übernehmen irgendwelche Haftungsansprüche.

Bitte beachten Sie auch diese Seiten:

[Impressum](#)

[Disclaimers & Copyright](#)

[Datenschutzerklärung](#)